Fernando C Fervenza

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7158309/publications.pdf

Version: 2024-02-01

182	14,581	28274	21540
papers	citations	55 h-index	114 g-index

186	186	186	8719
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis. New England Journal of Medicine, 2010, 363, 221-232.	27.0	2,275
2	KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney International, 2021, 100, S1-S276.	5.2	782
3	Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis. New England Journal of Medicine, 2013, 369, 417-427.	27.0	611
4	Membranoproliferative Glomerulonephritis â€" A New Look at an Old Entity. New England Journal of Medicine, 2012, 366, 1119-1131.	27.0	442
5	Rituximab-Induced Depletion of Anti-PLA2R Autoantibodies Predicts Response in Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2011, 22, 1543-1550.	6.1	403
6	Diagnosis of monoclonal gammopathy of renal significance. Kidney International, 2015, 87, 698-711.	5.2	339
7	The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nature Reviews Nephrology, 2019, 15, 45-59.	9.6	330
8	Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney International, 2021, 100, 753-779.	5.2	325
9	Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. New England Journal of Medicine, 2019, 381, 36-46.	27.0	324
10	A Proposal for a Serology-Based Approach to Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2017, 28, 421-430.	6.1	273
11	Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney International, 2013, 83, 749-756.	5.2	268
12	Rituximab Therapy in Idiopathic Membranous Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 2188-2198.	4.5	247
13	Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes and Endocrinology,the, 2019, 7, 128-139.	11.4	223
14	ANCA-associated vasculitis â€" clinical utility of using ANCA specificity to classify patients. Nature Reviews Rheumatology, 2016, 12, 570-579.	8.0	219
15	Neural epidermal growth factor-like 1 proteinÂ(NELL-1) associated membranous nephropathy. Kidney International, 2020, 97, 163-174.	5.2	213
16	Exostosin 1/Exostosin 2â€"Associated Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2019, 30, 1123-1136.	6.1	198
17	Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 95, 268-280.	5.2	198
18	Differentiating Primary, Genetic, and Secondary FSGS in Adults: A Clinicopathologic Approach. Journal of the American Society of Nephrology: JASN, 2018, 29, 759-774.	6.1	186

#	Article	IF	Citations
19	Membranous nephropathy. Nature Reviews Disease Primers, 2021, 7, 69.	30.5	167
20	A proposal for standardized grading of chronic changes in native kidney biopsy specimens. Kidney International, 2017, 91, 787-789.	5.2	161
21	Membranoproliferative Glomerulonephritis Secondary to Monoclonal Gammopathy. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 770-782.	4.5	156
22	C3 Glomerulonephritis Associated With Monoclonal Gammopathy: A Case Series. American Journal of Kidney Diseases, 2013, 62, 506-514.	1.9	150
23	Cryoglobulinaemia. Nature Reviews Disease Primers, 2018, 4, 11.	30.5	143
24	Semaphorin 3Bâ€“associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients. Kidney International, 2020, 98, 1253-1264.	5.2	138
25	Rituximab Versus Cyclophosphamide for ANCA-Associated Vasculitis with Renal Involvement. Journal of the American Society of Nephrology: JASN, 2015, 26, 976-985.	6.1	137
26	Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 95, 281-295.	5.2	135
27	COVID-19 Vaccination and Glomerulonephritis. Kidney International Reports, 2021, 6, 2969-2978.	0.8	135
28	Idiopathic Membranous Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 905-919.	4.5	126
29	Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptorÂantibodies. Kidney International, 2019, 95, 429-438.	5.2	123
30	The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis. Nature Communications, 2020, 11, 1600.	12.8	120
31	Treatment of membranous nephropathy: time for a paradigm shift. Nature Reviews Nephrology, 2017, 13, 563-579.	9.6	117
32	Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis. Annals of the Rheumatic Diseases, 2013, 72, 1342-1350.	0.9	109
33	DNAJB9 Is a Specific Immunohistochemical Marker for Fibrillary Glomerulonephritis. Kidney International Reports, 2018, 3, 56-64.	0.8	109
34	Dense Deposit Disease Associated With Monoclonal Gammopathy of Undetermined Significance. American Journal of Kidney Diseases, 2010, 56, 977-982.	1.9	107
35	C4d as a Diagnostic Tool in Proliferative GN. Journal of the American Society of Nephrology: JASN, 2015, 26, 2852-2859.	6.1	106
36	Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies. Nephrology Dialysis Transplantation, 2004, 19, 1288-1292.	0.7	104

#	Article	IF	Citations
37	The clinicopathologic characteristics and outcome of atypical anti-glomerular basement membrane nephritis. Kidney International, 2016, 89, 897-908.	5.2	95
38	Diffuse Alveolar Hemorrhage Secondary to Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis: Predictors of Respiratory Failure and Clinical Outcomes. Arthritis and Rheumatology, 2016, 68, 1467-1476.	5.6	94
39	A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P.) Tj ETQq1 1 0.784314 rgBT /Overlock 1 Transplantation, 2014, 29, 1570-1577.	0.7	92
40	Hematologic Characteristics of Proliferative Glomerulonephritides With Nonorganized Monoclonal Immunoglobulin Deposits. Mayo Clinic Proceedings, 2015, 90, 587-596.	3.0	92
41	Protocadherin 7â€“Associated Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2021, 32, 1249-1261.	6.1	92
42	Kidney Disease Caused by Dysregulation of the Complement Alternative Pathway. Journal of the American Society of Nephrology: JASN, 2015, 26, 2917-2929.	6.1	84
43	C3 Glomerulopathy: Ten Years' Experience at Mayo Clinic. Mayo Clinic Proceedings, 2018, 93, 991-1008.	3.0	82
44	Focal segmental glomerulosclerosis: towards a better understanding for the practicing nephrologist. Nephrology Dialysis Transplantation, 2015, 30, 375-384.	0.7	81
45	Thrombotic microangiopathy associated with monoclonal gammopathy. Kidney International, 2017, 91, 691-698.	5.2	78
46	Standardized classification and reporting of glomerulonephritis. Nephrology Dialysis Transplantation, 2019, 34, 193-199.	0.7	78
47	C3 glomerulopathy associated with monoclonal IgÂis a distinct subtype. Kidney International, 2018, 94, 178-186.	5.2	77
48	Outcomes of patients with renal monoclonal immunoglobulin deposition disease. American Journal of Hematology, 2016, 91, 1123-1128.	4.1	76
49	Diagnosis of complement alternative pathway disorders. Kidney International, 2016, 89, 278-288.	5.2	74
50	Recurrent Membranous Nephropathy After Kidney Transplantation. Transplantation, 2016, 100, 2710-2716.	1.0	69
51	Identifying Outcomes Important to Patients with Glomerular Disease and Their Caregivers. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 673-684.	4.5	66
52	Evidence from the Oxford Classification cohort supports the clinical value of subclassification ofÂfocal segmental glomerulosclerosis in IgAÂnephropathy. Kidney International, 2017, 91, 235-243.	5.2	62
53	Pathology of Renal Diseases Associated with Dysfunction of the Alternative Pathway of Complement: C3 Glomerulopathy and Atypical Hemolytic Uremic Syndrome (aHUS). Seminars in Thrombosis and Hemostasis, 2014, 40, 416-421.	2.7	61
54	Focal and segmental glomerulosclerosis: clinical and kidney biopsy correlations. CKJ: Clinical Kidney Journal, 2014, 7, 531-537.	2.9	60

#	Article	IF	Citations
55	Complement activation in pauci-immune necrotizing and crescentic glomerulonephritis: results of a proteomic analysis. Nephrology Dialysis Transplantation, 2017, 32, i139-i145.	0.7	59
56	Spectrum of manifestations of monoclonal gammopathy-associated renal lesions. Current Opinion in Nephrology and Hypertension, 2016, 25, 127-137.	2.0	57
57	In Patients with Membranous Lupus Nephritis, Exostosin-Positivity and Exostosin-Negativity Represent Two Different Phenotypes. Journal of the American Society of Nephrology: JASN, 2021, 32, 695-706.	6.1	56
58	Thrombotic Microangiopathy Care Pathway: A Consensus Statement for the Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy (CAP-TMA) Disease-Oriented Group. Mayo Clinic Proceedings, 2016, 91, 1189-1211.	3.0	55
59	Clinical and pathological phenotype of genetic causes of focal segmental glomerulosclerosis in adults. CKJ: Clinical Kidney Journal, 2018, 11, 179-190.	2.9	55
60	Congophilic Fibrillary Glomerulonephritis: A Case Series. American Journal of Kidney Diseases, 2018, 72, 325-336.	1.9	55
61	Histologic classification of glomerular diseases: clinicopathologic correlations, limitations exposed by validation studies, and suggestions for modification. Kidney International, 2014, 85, 779-793.	5.2	54
62	Therapeutic trials in adult FSGS: lessons learned and the road forward. Nature Reviews Nephrology, 2021, 17, 619-630.	9.6	53
63	Henoch-Schonlein purpura nephritis. International Journal of Dermatology, 2003, 42, 170-177.	1.0	52
64	Idiopathic membranoproliferative glomerulonephritis: does it exist?. Nephrology Dialysis Transplantation, 2012, 27, 4288-4294.	0.7	51
65	Proteomic Analysis of Complement Proteins in Membranous Nephropathy. Kidney International Reports, 2020, 5, 618-626.	0.8	51
66	A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR). Nephron, 2015, 130, 159-168.	1.8	49
67	Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits is associated with high rate of early recurrence in the allograft. Kidney International, 2018, 94, 159-169.	5.2	49
68	Membranous Nephropathy: Approaches to Treatment. American Journal of Nephrology, 2018, 47, 30-42.	3.1	48
69	Efficacy of Rituximab and Plasma Exchange in Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis with Severe Kidney Disease. Journal of the American Society of Nephrology: JASN, 2020, 31, 2688-2704.	6.1	48
70	Hematopoietic Stem Cell Transplant-Membranous Nephropathy Is Associated with Protocadherin FAT1. Journal of the American Society of Nephrology: JASN, 2022, 33, 1033-1044.	6.1	47
71	Incidence, prevalence, mortality and chronic renal damage of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in a 20-year population-based cohort. Nephrology Dialysis Transplantation, 2019, 34, 1508-1517.	0.7	46
72	C4 Nephritic Factors in C3 Glomerulopathy: A Case Series. American Journal of Kidney Diseases, 2017, 70, 834-843.	1.9	45

#	Article	IF	Citations
73	Successful Treatment of Patients With Refractory PLA2R-Associated Membranous Nephropathy With Obinutuzumab: A Report of 3 Cases. American Journal of Kidney Diseases, 2020, 76, 883-888.	1.9	45
74	A Target Antigenâ€"Based Approach to the Classification of Membranous Nephropathy. Mayo Clinic Proceedings, 2021, 96, 577-591.	3.0	45
75	IgG4-Related Tubulointerstitial Nephritis With Membranous Nephropathy. American Journal of Kidney Diseases, 2011, 58, 320-324.	1.9	42
76	Clinical, biopsy, and mass spectrometry characteristics of renal apolipoprotein A-IVÂamyloidosis. Kidney International, 2016, 90, 658-664.	5.2	42
77	The Incidence of Primary vs Secondary Focal Segmental Glomerulosclerosis: A Clinicopathologic Study. Mayo Clinic Proceedings, 2017, 92, 1772-1781.	3.0	39
78	Global glomerulosclerosis with nephrotic syndrome; the clinical importance of ageÂadjustment. Kidney International, 2018, 93, 1175-1182.	5.2	39
79	Health-related quality of life in glomerular disease. Kidney International, 2019, 95, 1209-1224.	5.2	38
80	IgD Heavy-Chain Deposition Disease. Journal of the American Society of Nephrology: JASN, 2015, 26, 784-790.	6.1	35
81	Induction of Heme Oxygenase-1 and Ferritin in the Kidney in Warm Antibody Hemolytic Anemia. American Journal of Kidney Diseases, 2008, 52, 972-977.	1.9	33
82	Persistent Microscopic Hematuria as a Risk Factor for Progression of IgA Nephropathy: New Floodlight on a Nearly Forgotten Biomarker. Journal of the American Society of Nephrology: JASN, 2017, 28, 2831-2834.	6.1	33
83	Rate and Predictors of Finding Monoclonal Gammopathy of Renal Significance (MGRS) Lesions on Kidney Biopsy in Patients with Monoclonal Gammopathy. Journal of the American Society of Nephrology: JASN, 2020, 31, 2400-2411.	6.1	33
84	Safety and Efficacy of Daratumumab in Patients with Proliferative GN with Monoclonal Immunoglobulin Deposits. Journal of the American Society of Nephrology: JASN, 2021, 32, 1163-1173.	6.1	33
85	Non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy. Journal of Renal Injury Prevention, 2017, 6, 18-25.	0.2	32
86	Association of a Novel Complement Factor H Mutation With Severe Crescentic and Necrotizing Glomerulonephritis. American Journal of Kidney Diseases, 2012, 60, 126-132.	1.9	31
87	Nephrotic syndrome redux. Nephrology Dialysis Transplantation, 2015, 30, 12-17.	0.7	30
88	Rituximab Exhibits Altered Pharmacokinetics in Patients With Membranous Nephropathy. Annals of Pharmacotherapy, 2019, 53, 357-363.	1.9	30
89	Characterization of C3 in C3 glomerulopathy. Nephrology Dialysis Transplantation, 2017, 32, gfw290.	0.7	29
90	Noninvasive Diagnosis of PLA2R-Associated Membranous Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1833-1839.	4.5	27

#	Article	IF	Citations
91	Serum levels of DNAJB9 are elevated in fibrillaryÂglomerulonephritis patients. Kidney International, 2019, 95, 1269-1272.	5.2	26
92	Bortezomib-induced acute interstitial nephritis. Nephrology Dialysis Transplantation, 2015, 30, 1225-1229.	0.7	25
93	Association of Pulmonary Hemorrhage, Positive Proteinase 3, and Urinary Red Blood Cell Casts With Venous Thromboembolism in Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis. Arthritis and Rheumatology, 2019, 71, 1888-1893.	5.6	25
94	Kidney biopsy chronicity grading in antineutrophil cytoplasmic antibody-associated vasculitis. Nephrology Dialysis Transplantation, 2022, 37, 1710-1721.	0.7	25
95	A Patient with Nephrotic-Range Proteinuria and Focal Global Glomerulosclerosis. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1979-1987.	4.5	24
96	Acute glomerulonephritis. Lancet, The, 2022, 399, 1646-1663.	13.7	24
97	C4 Glomerulopathy: A Disease Entity Associated WithÂC4dÂDeposition. American Journal of Kidney Diseases, 2016, 67, 949-953.	1.9	23
98	The impact of eculizumab on routine complement assays. Journal of Immunological Methods, 2018, 460, 63-71.	1.4	22
99	Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease. Biologics: Targets and Therapy, 2008, 2, 823.	3.2	21
100	Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis. Rheumatology, 2018, 57, 639-650.	1.9	20
101	Standardized Outcomes in Nephrologyâ€”Glomerular Disease (SONG-GD): establishing a core outcome set for trials in patients with glomerular disease. Kidney International, 2019, 95, 1280-1283.	5.2	20
102	Identification of Genetic Causes of Focal Segmental Glomerulosclerosis Increases With Proper Patient Selection. Mayo Clinic Proceedings, 2021, 96, 2342-2353.	3.0	20
103	Manifestations of Complement-Mediated and Immune Complex-Mediated Membranoproliferative Glomerulonephritis. Ophthalmology, 2016, 123, 1588-1594.	5.2	19
104	Immune-Complex Glomerulonephritis After COVID-19 Infection. Kidney International Reports, 2021, 6, 1170-1173.	0.8	19
105	Collagen IVÎ±345 dysfunction in glomerular basement membrane diseases. I. Discovery of a COL4A3 variant in familial Goodpastureâ€™s and Alport diseases. Journal of Biological Chemistry, 2021, 296, 100590.	3.4	19
106	C3 glomerulonephritis and autoimmune disease: more than a fortuitous association?. Journal of Nephrology, 2016, 29, 203-209.	2.0	18
107	The association of microhematuria with mesangial hypercellularity, endocapillary hypercellularity, crescent score and renal outcomes in immunoglobulin A nephropathy. Nephrology Dialysis Transplantation, 2021, 36, 840-847.	0.7	18
108	Diagnostic Utility of Complement Serology for Atypical Hemolytic Uremic Syndrome. Mayo Clinic Proceedings, 2018, 93, 1351-1362.	3.0	17

#	Article	IF	Citations
109	An Open-Label Pilot Study ofÂAdrenocorticotrophic Hormone inÂtheÂTreatment of IgA Nephropathy atÂHigh Risk of Progression. Kidney International Reports, 2020, 5, 58-65.	0.8	17
110	Longitudinal Changes in Health-Related Quality of Life in Primary Glomerular Disease: Results From the CureGN Study. Kidney International Reports, 2020, 5, 1679-1689.	0.8	17
111	Renal involvement in Neimann-Pick Disease. CKJ: Clinical Kidney Journal, 2009, 2, 448-451.	2.9	15
112	What are we missing in the clinical trials of focal segmental glomerulosclerosis?. Nephrology Dialysis Transplantation, 2017, 32, i14-i21.	0.7	15
113	C3 glomerulonephritis with a severe crescentic phenotype. Pediatric Nephrology, 2017, 32, 1625-1633.	1.7	15
114	Improving Clinical Trials for Anticomplement Therapies in Complement-Mediated Glomerulopathies: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. American Journal of Kidney Diseases, 2022, 79, 570-581.	1.9	15
115	Does tonsillectomy have a role in the treatment of patients with immunoglobulin A nephropathy?. Nephrology Dialysis Transplantation, 2014, 29, 1456-1459.	0.7	14
116	Recurrent Light Chain Proximal Tubulopathy in a KidneyÂAllograft. American Journal of Kidney Diseases, 2016, 68, 483-487.	1.9	14
117	Treatment of primary membranous nephropathy: where are we now?. Journal of Nephrology, 2018, 31, 489-502.	2.0	14
118	The longitudinal relationship between patient-reported outcomes and clinical characteristics among patients with focal segmental glomerulosclerosis in the Nephrotic Syndrome Study Network. CKJ: Clinical Kidney Journal, 2020, 13, 597-606.	2.9	14
119	Genomics Integration Into Nephrology Practice. Kidney Medicine, 2021, 3, 785-798.	2.0	13
120	Recurrence of DNAJB9-Positive Fibrillary Glomerulonephritis After Kidney Transplantation: A Case Series. American Journal of Kidney Diseases, 2020, 76, 500-510.	1.9	13
121	Recent Clinical Trials Insights into the Treatment of Primary Membranous Nephropathy. Drugs, 2022, 82, 109-132.	10.9	13
122	Association of Histologic Parameters with Outcome in C3 Glomerulopathy and Idiopathic Immunoglobulin-Associated Membranoproliferative Glomerulonephritis. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 994-1007.	4.5	13
123	Discontinuation of dialysis with eculizumab therapy in a pediatric patient with dense deposit disease. Pediatric Nephrology, 2016, 31, 683-687.	1.7	12
124	Treatment of fibrillary glomerulonephritis with rituximab: a 12-month pilot study. Nephrology Dialysis Transplantation, 2021, 36, 104-110.	0.7	12
125	Plasma exchange for the management of ANCA-associated vasculitis: the con position. Nephrology Dialysis Transplantation, 2021, 36, 231-236.	0.7	12
126	Histiocytic glomerulopathy associated with macrophage activation syndrome. CKJ: Clinical Kidney Journal, 2015, 8, 157-160.	2.9	11

#	Article	IF	Citations
127	COVID-19 and ANCA-associated vasculitis: recommendations for vaccine preparedness and the use of rituximab. Nephrology Dialysis Transplantation, 2021, 36, 1758-1760.	0.7	11
128	Rituximab in ANCA-Associated Vasculitis: Fad or Fact?. Nephron Clinical Practice, 2011, 118, c182-c188.	2.3	10
129	C3 Glomerulonephritis Associated With Complement Factor B Mutation. American Journal of Kidney Diseases, 2015, 65, 520-521.	1.9	10
130	Efficacy of Rituximab in Treatment-Resistant Focal Segmental Glomerulosclerosis With Elevated Soluble Urokinase-Type Plasminogen Activator Receptor and Activation of Podocyte Î²3 Integrin. Kidney International Reports, 2022, 7, 68-77.	0.8	10
131	Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression. Journal of the American Society of Nephrology: JASN, 2022, 33, 291-303.	6.1	10
132	Renal hemodynamic effects of the HMG-CoA reductase inhibitors in autosomal dominant polycystic kidney disease. Nephrology Dialysis Transplantation, 2016, 31, 1290-1295.	0.7	9
133	Rapidly progressive glomerulonephritis due to coexistent anti-glomerular basement membrane disease and fibrillary glomerulonephritis. CKJ: Clinical Kidney Journal, 2016, 9, 97-101.	2.9	9
134	Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitis. Therapeutic Advances in Musculoskeletal Disease, 2014, 6, 58-74.	2.7	8
135	Noninvasive Urinary Monitoring of Progression in IgA Nephropathy. International Journal of Molecular Sciences, 2019, 20, 4463.	4.1	8
136	Frequent-relapsing, steroid-dependent minimal change disease: is rituximab the answer?. Nephrology Dialysis Transplantation, 2014, 29, 722-727.	0.7	7
137	Overlap of ultrastructural findings in C3 glomerulonephritis and dense deposit disease. Kidney International, 2015, 88, 1449-1450.	5.2	7
138	C4d as a marker for masked immune deposits. Kidney International, 2016, 90, 223-224.	5.2	7
139	Kidney Biopsy Is Required for Nephrotic Syndrome with PLA2R+ and Normal Kidney Function: The Con View. Kidney360, 2020, 1, 890-893.	2.1	7
140	Development of an international Delphi survey to establish core outcome domains for trials in adults with glomerular disease. Kidney International, 2021, 100, 881-893.	5.2	7
141	Standardized reporting of monoclonal immunoglobulinâ€“associated renal diseases: recommendations from a Mayo Clinic/Renal Pathology Society Working Group. Kidney International, 2020, 98, 310-313.	5.2	7
142	Familial antiglomerular basement membrane disease in zero human leukocyte antigen mismatch siblings. Clinical Nephrology, 2017, 88, 277-283.	0.7	7
143	Circulating autoreactive proteinase 3+ B cells and tolerance checkpoints in ANCA-associated vasculitis. JCI Insight, 2021, 6, .	5.0	7
144	Treatment of ANCA-Associated Vasculitis: New Therapies and a Look at Old Entities. Advances in Chronic Kidney Disease, 2014, 21, 182-193.	1.4	6

#	Article	IF	Citations
145	Con: Biomarkers in glomerular diseases: putting the cart before the wheel?. Nephrology Dialysis Transplantation, 2015, 30, 885-890.	0.7	6
146	Leishmaniasis-Associated Membranoproliferative Glomerulonephritis With Massive Complement Deposition. Kidney International Reports, 2016, 1, 125-130.	0.8	6
147	CKD Due to a Novel Mitochondrial DNA Mutation: A Case Report. American Journal of Kidney Diseases, 2019, 73, 273-277.	1.9	6
148	Nail-patella-like renal disease masquerading as Fabry disease on kidney biopsy: a case report. BMC Nephrology, 2020, 21, 341.	1.8	6
149	PEXIVAS. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 307-309.	4.5	6
150	Atypical Antiglomerular Basement Membrane Nephritis Following Immune Checkpoint Inhibitor. Kidney International Reports, 2022, 7, 1913-1916.	0.8	6
151	The characteristics of seronegative and seropositive non-hepatitis-associated cryoglobulinemic glomerulonephritis. Kidney International, 2022, 102, 382-394.	5.2	6
152	Refining phenotypes in ANCA-associated vasculitis. Nature Reviews Nephrology, 2013, 9, 6-8.	9.6	5
153	American Society of Nephrology Quiz and Questionnaire 2012. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1460-1465.	4.5	5
154	Comparison of treatment options in adults with frequently relapsing or steroid-dependent minimal change disease. Nephrology Dialysis Transplantation, 2021, 36, 1821-1827.	0.7	5
155	Kidney Histopathology in ANCA-Associated Vasculitides Treated with Plasma Exchange. Journal of the American Society of Nephrology: JASN, 2022, 33, 1223-1224.	6.1	5
156	Limited Significance of Antifactor H Antibodies in Patients with Membranous Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 939-941.	4.5	4
157	A Core Outcome Set for Trials in Glomerular Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 53-64.	4.5	4
158	Disease Progression and End-Stage Renal Disease in Diverse Glomerulopathies. Mayo Clinic Proceedings, 2018, 93, 133-135.	3.0	3
159	Open-Label Clinical Trials of Oral Pulse Dexamethasone for Adults with Idiopathic Nephrotic Syndrome. American Journal of Nephrology, 2019, 49, 377-385.	3.1	3
160	APOL1 genotype-associated morphologic changes among patients with focal segmental glomerulosclerosis. Pediatric Nephrology, 2021, 36, 2747-2757.	1.7	3
161	Crystal-Induced Podocytopathy Producing Collapsing Focal Segmental Glomerulosclerosis in Monoclonal Gammopathy of Renal Significance: A Case Report. Kidney Medicine, 2021, 3, 659-664.	2.0	3
162	Novel Genetic Variants in Complement-Mediated Thrombotic Microangiopath. Blood, 2015, 126, 1050-1050.	1.4	3

#	Article	IF	Citations
163	High-dose melphalan and autologous hematopoietic stem cell transplant in patientÂwith C3 glomerulonephritis associatedÂwith monoclonal gammopathy. Clinical Nephrology, 2018, 89, 291-299.	0.7	3
164	Advances in basic science and translational medicine. Nature Reviews Nephrology, 2015, 11, 67-68.	9.6	2
165	Renal biopsy findings in patients with extreme obesity: more heterogeneous than youÂthink. Kidney International, 2019, 95, 495-498.	5.2	2
166	1H Nuclear Magnetic Resonance Spectroscopy-Based Methods for the Quantification of Proteins in Urine. Analytical Chemistry, 2021, 93, 13177-13186.	6.5	2
167	A focus group study of self-management in patients with glomerular disease.. Kidney International Reports, 2021, 7, 56-67.	0.8	2
168	â€œPresumedâ€•Primary Focal Segmental Glomerulosclerosis: A Novel Nuance for Steroid Therapy. Kidney International Reports, 2022, 7, 9-12.	0.8	2
169	Complement Gene Variant Effect on Relapse of Complement-Mediated Thrombotic Microangiopathy after Eculizumab Cessation. Blood Advances, 2022, , .	5.2	2
170	Opponent's comments. Nephrology Dialysis Transplantation, 2015, 30, 898-899.	0.7	1
171	SP003GENETIC TESTING IN SUSPECTED HEREDITARY PROTEINURIC KIDNEY DISEASES. Nephrology Dialysis Transplantation, 2018, 33, i346-i347.	0.7	1
172	Determination of Relapse Risk By Complement Gene Variants after Eculizumab Discontinuation in Complement-Mediated Thrombotic Microangiopathy: A Retrospective Review. Blood, 2020, 136, 25-26.	1.4	1
173	American Society of Nephrology Quiz and Questionnaire 2013. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 987-996.	4.5	0
174	The Authors Reply. Kidney International, 2017, 92, 517.	5.2	0
175	The authors reply. Kidney International, 2018, 94, 632-633.	5.2	0
176	Editorial: a new era in anti-neutrophil cytoplasmic antibody vasculitis. Nephrology Dialysis Transplantation, 2019, 34, 379-381.	0.7	0
177	C3 Glomerulonephritis: A Rare Etiology of the Pulmonary Renal Syndrome. Kidney Medicine, 2019, 1, 36-39.	2.0	0
178	Nonrecurrent Early Post-Transplantation Focal Segmental Glomerulosclerosis. Kidney International Reports, 2020, 5, 1518-1525.	0.8	0
179	Primary Nephrotic Syndrome. Nephrology Self-assessment Program: NephSAP, 2020, 19, 68-76.	3.0	0
180	A Single-Center Phase 2 Open-Label Trial Evaluating the Safety and Efficacy of Daratumumab in Treatment of Patients with Monoclonal Gammopathy of Renal Significance. Blood, 2020, 136, 43-44.	1.4	0

#	Article	IF	Citations
181	Membranous Nephropathy. , 0, , 158-169.		0
182	Molecular Characterization of Membranous Nephropathy: Quo Vadis?. Journal of the American Society of Nephrology: JASN, 2022, 33, 1057-1059.	6.1	0